Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Horizon scan of T-cell lymphoma therapy

Deepa Jagadeesh, MD, PhD, Case Comprehensive Cancer Center, Cleveland, OH, comments on the future of upfront treatments for T-cell lymphomas, in particular highlighting a study of Pi3 kinase in the upfront setting. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Deepa Jagadeesh, MD, PhD, has received research funding from ADC Therapeutics, AstraZeneca, Debiopharm Group, MEI Pharma, Regeneron, Rhizen Pharma, Seagen, Trillium Therapeutics and LOXO Pharma.